



## JASN Abstract Supplement ASN Kidney Week 2011 November 8 – 13, 2011

### Abstract Publication

More than 4,000 abstracts are published in this supplement. Abstracts are arranged by the abstract type\*\*, then by presentation date\*, and then by chronological publication number. Abstracts with a "PUB" number will not be presented at the ASN Annual Meeting.

\* TH = Thursday, FR = Friday, SA = Saturday

\*\* OR = Oral, PO = Poster, PUB = Publication Only

The presenting author's name is underlined. For the poster sessions, the publication numbers and poster board numbers are the same.

### Abstract Author Index

The Author Index lists all abstract authors in alphabetical order. To locate an abstract, first reference the abstract type (OR, PO, or PUB) and then the presentation day (TH, FR, or SA), and then the chronological publication number.

### Abstract Subject Index

The Subject Index lists major keywords from each abstract in alphabetical order. To locate an abstract, first reference the abstract type (OR, PO, or PUB) and then the presentation day (TH, FR, or SA), and then the chronological publication number.

### Abstract Reference Format

To cite abstracts in this publication, please use the following format: Author Names: Abstract Title [Abstract]. *J Am Soc Nephrol* 22, 2011: Page(s).

For example: Parapas NA, Qui A, Barasch JM: The Kidney Defends the Urinary System from Infection by Secreting NGAL [Abstract]. *J Am Soc Nephrol* 22, 2011: 1A.

### Abstract Experts

Abstract submissions were rigorously reviewed and graded by multiple experts. ASN thanks the abstract category chairs and reviewers for assistance with the abstract process. The *Onsite Program* lists all abstract experts.

### Abstract Disclaimer and Copyright

The Abstract Issue of JASN® contains proprietary information belonging to the American Society of Nephrology (ASN). It is published as a service for the personal, noncommercial, and informational use only of its members and Kidney Week participants. Any commercial use is strictly prohibited. ASN's program materials and publications facilitate scientific discourse for educational purposes. ASN accepts no responsibility for any products, presentations, opinions, statements, or positions expressed, and inclusion of such material within Kidney Week and other ASN publications, or online postings does not constitute an endorsement by ASN.

### ASN General Information

#### Kidney Week Program and Presentations

The Kidney Week 2011 program, which can be found in the *Onsite Program*, includes:

- Early Programs' content
- Plenary Sessions
- Basic and Clinical Science Symposia
- Clinical Nephrology Conferences
- Special Sessions
- Educational Symposia
- Late-Breaking Clinical Trials Session
- Oral Abstract Sessions
- Poster Sessions

#### Disclosure Statement

ASN requires all individuals in a position to control content for Kidney Week 2011 to complete a disclosure form. Responses are listed in the Kidney Week 2011 *Disclosure Digest*, which is available to each meeting participant.

#### Program Builder

All abstracts and the complete Kidney Week 2011 program are viewable online through the Program Builder at [www.asn-online.org/KidneyWeek](http://www.asn-online.org/KidneyWeek) with features including keyword search and PDA download. Support is provided by Mitsubishi Tanabe Pharma.

#### Top Abstracts — New for 2011

ASN is pleased to award Top Abstracts for young investigators and physicians-in-training as lead authors. The *Onsite Program* lists all top oral and poster presentations by young investigators and physicians-in-training as lead authors.

#### Posters On-Demand™ — New for 2011

Fully paid participants can access electronic versions of the Kidney Week 2011 posters at no additional cost. Search and locate posters easily by authors, categories, or keywords during and after the meeting. Posters can be accessed online at [www.asn-online.org/KidneyWeek/PostersOnDemand](http://www.asn-online.org/KidneyWeek/PostersOnDemand).

Support is provided by Amgen, Genentech, a Member of the Roche Group, and Mitsubishi Tanabe Pharma.

#### Trademark

The American Society of Nephrology®, ASN®, Kidney Week®, CJASN®, JASN®, NephSAP®, and ASN Kidney News® are registered trademarks of ASN.

#### Contact ASN

American Society of Nephrology  
1510 H Street, NW, Suite 800  
Washington, DC 20005  
202-640-4660 phone, 202-637-9793 fax  
[email@asn-online.org](mailto:email@asn-online.org), [www.asn-online.org](http://www.asn-online.org)

**PUB288**

**Views of Renal Healthcare Professionals About the Role of Palliative Care in Patients with End Stage Kidney Disease** Robert G. Fassett,<sup>1</sup> Iain Robertson,<sup>2</sup> Rosalind M. Bull,<sup>3</sup> <sup>1</sup>*Renal Medicine, Royal Brisbane and Women's Hospital and The University of Queensland, Brisbane, Queensland, Australia;* <sup>2</sup>*Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia;* <sup>3</sup>*School of Nursing and Midwifery, University of Tasmania, Launceston, Tasmania, Australia.*

**Background:** Palliative care is increasingly recognized as an important part of end stage kidney disease (ESKD) care. Health professionals' own beliefs and knowledge about palliative care, death and dying impact on their decision to offer and support palliative care involvement. This study explored the perceptions of renal health professionals regarding palliative care and how this influenced how palliative care was integrated into ESKD patient management. The aim of this study was to identify barriers and facilitators experienced by renal healthcare professionals to incorporating palliative care into ESKD management.

**Methods:** All renal healthcare professionals in North and Northwest Tasmania were invited to complete a questionnaire exploring their views on the role of palliative care in the management of patients with CKD.

**Key:** TH - Thursday; FR - Friday; SA - Saturday; OR - Oral Abstract; PO - Poster; PUB - Publication Only  
Underline represents presenting author.

**Results:** Of 105 surveys distributed 41 were completed (response rate 39%). Health professionals' beliefs that emerged included; Loss of will to live was the greatest influence on dialysis withdrawal. Loss of will to live mainly followed pain and depression. Acute comorbidity or depression delayed withdrawal of treatment. Malignancy and functional decline influence health professionals and family towards palliation. End of life care should be discussed early at pre-dialysis education, openly, honestly and sensitively with full disclosure by senior renal medical or nursing staff. Final decisions should occur depending on the patient's ongoing condition. The patient should make the decision supported by family.

**Conclusions:** Renal health professionals believed the patient, with involvement of the family, should make end of life decisions. Preparation should occur at the start of ESKD management with the actual decision made when the patient is ready.

*Funding:* Government Support - Non-U.S.